You are here

News

July 25, 2012
MHRP Scientist Wins 2012 NIDA Avant-Garde Award for Combination Anti-Heroin/HIV Vaccine

Dr. Gary R. Matyas has been selected the 2012 recipient of the NIDA Avant-Garde Award for Medications Development. Matyas proposes to develop an effective, safe and easily manufactured combination anti-heroin/HIV vaccine that could treat heroin addiction while at the same time prevent HIV infection in those receiving the vaccine. Matyas will receive $1,000,000 per year for five years to...

July 22, 2012
AIDS 2012

From July 22-27, the XIX International AIDS Conference (AIDS 2012) will convene more than 20,000 delegates from nearly 200 countries in Washington, D.C.

The AIDS 2012 programme will present new scientific knowledge and offer many opportunities for structured dialogue on the major issues facing the global response to HIV. Below is a list of MHRP-related activities:

Satellite...

June 5, 2012
In Memory of our Nigerian Colleagues

MHRP is deeply saddened by the loss of four colleagues in the June 3 plane crash in Lagos, Nigeria. Anthony Okara, Benson Oluwayomi, Obinna Akubueze and Talwo Lamidi from MHRP’s site in Nigeria, Walter Reed Program-Nigeria, were en route from Abuja to Lagos to attend a workshop. We appreciate their many contributions to efforts to improve the health of people in Nigeria through their work on...

June 1, 2012
MUWRP Celebrates Ten Years of Progress

MUWRP celebrated 10 years of progress in research and HIV prevention, treatment and care at a ceremony held at the College of Health Sciences quadrangle in Kampala. 

The event included a scientific lecture on Thai HIV vaccine trial (RV 144) and presentations on milestones achieved over the decade (2002 – 2012) in the different programs. 

It was officiated by the Director of the U...

May 31, 2012
Lancet Article Explores Efficacy Variables in RV144

In the 30 May issue of The Lancet Infectious Diseases, MHRP researchers and collaborators provide important insights on behavioral and time variables that may have influenced the efficacy seen in the RV144 HIV vaccine study.

In an accompanying editorial, José Esparza of the Bill and Melinda Gates Foundation notes that “The article by Robb et al is important, not only because it adds...

May 16, 2012
Time for an HIV Vaccine

Deployed U.S. forces have historically been exposed to diseases that are not prevalent in the U.S. such as malaria, leishmaniasis and dengue. To combat these disease threats, the U.S. military has excelled at infectious disease research and spurred some of medicine’s greatest advances in disease prevention, diagnostics, and treatment.

When the HIV epidemic first emerged in the 1980s,...

April 23, 2012
Human Clinical Trial of a New DNA-MVA Vaccine Candidate Begins in Africa

A Phase I clinical trial beginning this month in Kericho, Kenya and later in Tanzania and Uganda, will evaluate a new vaccine combination. Together, these two vaccines aim to protect against diverse subtypes of HIV-1 prevalent in Africa, as well as North America, Europe, Asia and South America. 

This small-scale trial, called RV262, will enroll 80 volunteers in East Africa, and will...

April 11, 2012
RV144 Follow-up Study RV305 Begins in Thailand

Screening for a new clinical study, called RV305, recently began at the Bang Lamung Hospital in the Chonburi Province of Thailand. This small immunogenicity study will evaluate extended boosting regimens using the same vaccine components that were used in RV144.  The goal of the secondary boost is to try to extend and increase the immune response seen in RV144.

This is the first of two...

April 4, 2012
Laboratory Studies Provide Possible Explanation for How the RV144 Vaccine Regimen May Have Protected Against HIV

Researchers have discovered important clues about the immune responses that may have played a role in protecting some volunteers from HIV in the RV144 Thai trial. Results from extensive RV144 laboratory studies were published today in the New England Journal of Medicine.

The RV144 study in Thailand was the first HIV vaccine trial to show some effectiveness in preventing HIV infection. “...

March 13, 2012
CROI 2012 Wrap Up

More than 4,000 researchers and clinicians from around the world gathered in Seattle from March 5-8, 2012 for the 19th Conference on Retroviruses and Opportunistic Infections (CROI). See what MHRP presented:

Immune correlates of infection risk in the Thai phase III ALVAC-HIB/ AIDSVAX-B/E prime boost study 

Nelson Michael

Watch video (2nd presentation) 

Prospectively...

Pages